DAVITA INC.
About DAVITA INC.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $13.6B
- Net income
- $746.8M
- Total assets
- $17.5B
- Market cap
- $12.3B
- Operating margin
- 15.0%
- Net margin
- 7.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $13.6B
- Operating expenses
- $11.6B
- Operating income
- $2.0B
- Income tax
- $293.1M
- Net income
- $1.1B
- EPS (basic)
- $10.06
- EPS (diluted)
- $9.84
Balance sheet
- Total assets
- $17.5B
- Current assets
- $4.1B
- Total liabilities
- $16.3B
- Current liabilities
- $3.1B
- Shareholders’ equity
- -$373.7M
Cash flow
- Operating cash flow
- $1.9B
- Investing cash flow
- -$654.9M
- Financing cash flow
- -$1.4B
- Net cash flow
- -$143.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.3B
- P/E ratio
- 19.5
- EPS (diluted)
- $9.84
- Shares outstanding
- 64.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 31, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $746.8M in FY2025.
- Revenue grew 17% from FY2021 to FY2025.
- Trading 4% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 19.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DAVITA INC..
Write a review
News about DAVITA INC.
News & sentiment via Polygon.io
